-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/fiber-intake-prepub-final-research-appendix-c.xlsx
January 01, 2024 - Community 40–65 y; BMI 20–35 kg/m2, habitual WG consumption <24 g/d Diabetes, heart, renal, bowel, liver … , use of medication for dyslipidaemia, T2D or hypertension, diseases including gastrointestinal and liver … the food provided in the study; with or history of endocrine, cardiovascular, arterial hypertension, liver … Pregnancy, Allergies including food allergies, Metal implants, Chronic disease of heart, kidney, or liver … COI) Community nonsmoking, weight-stable males aged 35–55 y history or presence of kidney disease, liver
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/fiber-intake-final-appendix-c.xlsx
January 01, 2024 - Community 40–65 y; BMI 20–35 kg/m2, habitual WG consumption <24 g/d Diabetes, heart, renal, bowel, liver … COI) Community nonsmoking, weight-stable males aged 35–55 y history or presence of kidney disease, liver … , use of medication for dyslipidaemia, T2D or hypertension, diseases including gastrointestinal and liver … the food provided in the study; with or history of endocrine, cardiovascular, arterial hypertension, liver … Pregnancy, Allergies including food allergies, Metal implants, Chronic disease of heart, kidney, or liver
-
digital.ahrq.gov/ahrq-funded-projects/integrated-closed-loop-feedback-system-pediatric-cardiometabolic-disease
January 01, 2023 - Patient-Reported Outcomes
Cardiometabolic disease, which includes obesity, diabetes, impaired liver
-
hcup-us.ahrq.gov/reports/pubsearch/advanced.jsp
May 01, 2020 - 2019 or 2017, 2018, 2019)
Abstract (Examples: alcohol use disorders, inflammatory bowel disease, liver
-
hcup-us.ahrq.gov/db/nation/nis/tools/stats/FileSpecifications_NIS_2008_Severity.TXT
January 01, 2008 - NIS 2008 Severity 24 CM_LIVER 91 92 Num AHRQ comorbidity measure: Liver
-
hcup-us.ahrq.gov/db/nation/nis/tools/stats/FileSpecifications_NIS_2009_Severity.TXT
January 01, 2009 - NIS 2009 Severity 24 CM_LIVER 91 92 Num AHRQ comorbidity measure: Liver
-
hcup-us.ahrq.gov/db/nation/kid/tools/stats/FileSpecifications_KID_2009_Severity.TXT
January 01, 2009 - KID 2009 Severity 24 CM_LIVER 85 86 Num AHRQ comorbidity measure: Liver
-
effectivehealthcare.ahrq.gov/sites/default/files/nonopioid-chronic-pain-apf2_0.xlsx
January 01, 2018 - Placebo-Controlled Trials
WAE WAE SAE SAE CV Events CV Events CV Events CV Events GI GI GI GI Liver … Dysfunction Liver Dysfunction Liver Dysfunction Liver Dysfunction Renal Dysfunction Renal Dysfunction … Acetaminophen - Placebo-Controlled Trials
WAE WAE SAE SAE Liver Toxicity Liver Toxicity Liver … Toxicity Liver Toxicity
Author, Year Quality Pain Population Drug Assessment Time (wk) Time Category … Dysfunction Liver Dysfunction Liver Dysfunction Liver Dysfunction Renal Dysfunction Renal Dysfunction
-
hcup-us.ahrq.gov/datainnovations/raceethnicitytoolkit/or26.jsp
August 01, 2014 - were in the top five causes for Whites, but did not appear in the top five for AI/ANs, while chronic liver … Unintentional injury and chronic liver disease were notable for even higher disparities (rate ratios … From least to most common causes, for 1990 to 1999, AI/AN: chronic lower respiratory disease, chronic liver … are all causes, C V D, cancer, unintentional injury, chronic lower respiratory disease, and chronic liver
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/TkWNoq6KQb3SoZ54gscLCQ
July 25, 2016 - Clin
Liver Dis (Hoboken). 2018;12(1):1-4. doi:10.1002/cld.
732
7. … Hui CK, Leung N, Shek WH, et al; Hong Kong
Liver Fibrosis Study Group. … progression to
liver complications. … Efficacy of
low-dose alpha interferon therapy in HBV-related
chronic liver disease in Asian Indians: … Lamivudine for patients with chronic hepatitis B
and advanced liver disease.
-
hcup-us.ahrq.gov/toolssoftware/procedure/pc2015.csv
January 01, 2012 - BIOPSY 1
'5012' OPEN LIVER BIOPSY 3
'5013' TRANSJUGULAR LIVER BX (Begin 2007) 1
'5014' LAPAROSCOPIC … HEPATECTOMY 4
'5023' OPN ABLTN LIVER LES/TISS (Begin 2006) 4
'5024' PERC ABLTN LIVER LES/TIS (Begin … 2006) 4
'5025' LAP ABLTN LIVER LES/TISS (Begin 2006) 4
'5026' ABLTN LIVER LES/TISS NEC (Begin 2006 … TRANSPL 4
'5059' LIVER TRANSPLANT NEC 4
'5061' CLOSURE LIVER LACERAT 4
'5069' LIVER REPAIR NEC 4 … '5091' PERCUTAN LIVER ASPIRAT 2
'5092' EXTRACORPOR HEPAT ASSIS 2
'5093' LOCAL PERFUSION LIVER 2
'
-
psnet.ahrq.gov/node/49617/psn-pdf
January 01, 2011 - age, gender,
weight, muscle metabolism, and protein intake.(4) Specifically, patients with end-stage liver … Scr may not reflect renal function in patients with reduced muscle mass, malnutrition, and end-stage
liver
-
psnet.ahrq.gov/node/49486/psn-pdf
August 21, 2005 - Second, warfarin is metabolized in the liver by the P450 cytochrome CYP2C9. … approximately 7 to 9 days before the warfarin level or INR reaches a steady state.(4) Patients with liver … factors
associated with lower warfarin requirements include a body mass index (BMI) less than 20, liver
-
hcup-us.ahrq.gov/db/nation/neds/stats/NEDS_2015Q4_IP_MaskedStats.PDF
October 01, 2015 - MAJ O.R. 1,893 0.18
4: TRACH W MV >96 HRS OR PDX EXC FACE, MOUTH & NECK W/O MAJ O.R. 1,519 0.15
5: LIVER … & SHUNT PROCEDURES W MCC 165 0.02
406: PANCREAS, LIVER & SHUNT PROCEDURES W CC 88 0.01
407: PANCREAS … , LIVER & SHUNT PROCEDURES W/O CC/MCC 35 0.00
408: BILIARY TRACT PROC EXCEPT ONLY CHOLECYST W OR W/O … EXCEPT MALIG,CIRR,ALC HEPA W MCC 2,036 0.20
442: DISORDERS OF LIVER EXCEPT MALIG,CIRR,ALC HEPA W CC … 2,605 0.25
443: DISORDERS OF LIVER EXCEPT MALIG,CIRR,ALC HEPA W/O CC/MCC 805 0.08
444: DISORDERS OF
-
hcup-us.ahrq.gov/db/nation/neds/stats/NEDS_2016_IP_MaskedStats.PDF
January 01, 2016 - MAJ O.R. 8,052 0.19
4: TRACH W MV >96 HRS OR PDX EXC FACE, MOUTH & NECK W/O MAJ O.R. 6,651 0.15
5: LIVER … TRANSPLANT W MCC OR INTESTINAL TRANSPLANT 197 0.00
6: LIVER TRANSPLANT W/O MCC 24 0.00
7: LUNG TRANSPLANT … , LIVER & SHUNT PROCEDURES W/O CC/MCC 144 0.00
408: BILIARY TRACT PROC EXCEPT ONLY CHOLECYST W OR W/ … EXCEPT MALIG,CIRR,ALC HEPA W MCC 8,238 0.19
442: DISORDERS OF LIVER EXCEPT MALIG,CIRR,ALC HEPA W CC … 10,368 0.24
443: DISORDERS OF LIVER EXCEPT MALIG,CIRR,ALC HEPA W/O CC/MCC 3,037 0.07
444: DISORDERS
-
hcup-us.ahrq.gov/db/nation/neds/stats/NEDS_2018_IP_MaskedStats.PDF
January 01, 2018 - MAJ O.R. 8,409 0.17
4: TRACH W MV >96 HRS OR PDX EXC FACE, MOUTH & NECK W/O MAJ O.R. 6,800 0.13
5: LIVER … TRANSPLANT W MCC OR INTESTINAL TRANSPLANT 149 0.00
6: LIVER TRANSPLANT W/O MCC 25 0.00
7: LUNG TRANSPLANT … , LIVER & SHUNT PROCEDURES W/O CC/MCC 85 0.00
408: BILIARY TRACT PROC EXCEPT ONLY CHOLECYST W OR W/O … EXCEPT MALIG,CIRR,ALC HEPA W MCC 11,617 0.23
442: DISORDERS OF LIVER EXCEPT MALIG,CIRR,ALC HEPA W CC … 13,014 0.26
443: DISORDERS OF LIVER EXCEPT MALIG,CIRR,ALC HEPA W/O CC/MCC 3,580 0.07
444: DISORDERS
-
www.uspreventiveservicestaskforce.org/uspstf/recommendation/hepatitis-b-in-pregnant-women-screening-2009
June 15, 2009 - infections increase long-term morbidity and mortality by predisposing infected persons to cirrhosis of the liver … and liver cancer.
-
psnet.ahrq.gov/issue/outcomes-associated-nationwide-introduction-rapid-response-systems-netherlands
January 18, 2013 - Sepsis
May 31, 2023
Using an MET service to manage hemorrhage post-percutaneous liver
-
psnet.ahrq.gov/issue/contextual-errors-and-failures-individualizing-patient-care-multicenter-study
October 29, 2012 - January 19, 2012
WebM&M Cases
Liver Failure After Chemotherapy
-
www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/low-dose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-preventive-medication
September 26, 2019 - Outcomes
Maternal outcomes:
Preeclampsia; preeclampsia with severe features
Hemolysis, elevated liver